Biotech. Stocks Recap: Cleveland BioLabs, Progenics Pharmaceuticals, NewLink Genetics Corp, StemCells

Lakeway, TX -- (SBWIRE) -- 03/01/2013 -- vbtrendreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Cleveland BioLabs, Inc.(NASDAQ:CBLI) is lower 1.28% to $1.53. Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology drug development. The Company’s lead drug candidate CBLB502 is developed for dual indications under the United States Food & Drug Administration's (FDA's) Animal Efficacy Rule, commonly referred to as the Animal Rule, as a radiation countermeasure, and under the FDA's traditional drug approval pathway as an anti-cancer agent and an oncology supportive care therapy.

How Should Investors Trade CBLI After The Solid Jump? Let’s Find Out Here

Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX) is higher 3.79% to $2.74. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection.

Is PGNX Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here

NewLink Genetics Corp(NASDAQ:NLNK) is lower 0.09% and is trading at $11.76. NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians.

Is NLNK Buy After The Recent Price Movement? Find Out Here

StemCells, Inc.(NASDAQ:STEM) added 0.01% and is trading at $1.71. StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development.

Is STEM Buy After The Recent Price Movement? Find Out Here

About vbtrendreport.com
vbtrendreport.com’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by vbtrendreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vbtrendreport.com does expect that investors will buy and sell securities based on information assembled and presented in vbtrendreport.com. PLEASE always do your own due diligence, and consult your financial advisor.